SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: A pilot study

Abstract

In this pilot study in patients with TEE-guided cardioversion, the use of fondaparinux appeared to be well tolerated, with similar efficacy to UFH+VKA. Furthermore, a trend to greater thrombus resolution was observed.

Oral anticoagulation and left atrial thrombi resolution in nonrheumatic atrial fibrillation or flutter: A systematic review and meta‐analysis

“…The flowchart of the systematic review is depicted in Figure . Of the 8,468 articles screened, 17 articles were selected for the final analyses . The initial and follow‐up data of the articles included in the final analyses are listed in Table and in Table , respectively.…”

“…There were no randomized controlled trials of OAC agents and/or doses. One randomized controlled trial compared subcutaneous fondaparinux to intravenous unfractionated heparin plus oral VKA in subjects with AF who had been diagnosed with LAT on TEE prior to anticipated cardioversion . Additional data with DOACs are needed before they may be considered first‐line alternatives to warfarin.…”

Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India

“…Fondaparinux appeared to be well tolerated and showed a similar efficacy to unfractionated heparin and vitamin K antagonist. A trend of greater thrombus resolution was also observed [ 32 ]. Fondaparinux also appears to be a safe alternative to heparin to prevent graft failure after CABG [ 33 ].…”

Effective use of fondaparinux in patient with unresponsiveness to nadroparin

“…The evidence for the use of parenteral anticoagulants with respect to AF is limited 3 . Fondaparinux has been successfully used as a single anticoagulant prior to transoesophageal echocardiography‐guided cardioversion (total treatment time of 28‐56 days), 4 and one study revealed the non‐inferiority of enoxaparin compared to UFH + warfarin in similar clinical settings 5 …”